Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

SAMIK PHARM. CO.,LTD.

삼익제약014950KOSDAQSector: Pharma & Biotech
₩5,97012.59%Market cap ₩60.1BAs of Sep 2, 2026 close · updated once daily
Market cap
₩60.1B
#1026 in KOSDAQ
Loss
PER not computable
1.00x
Sector median 1.61x
0.3%
Sector median 0.0%
A
Grade A64.5 ptsTop 23% of 2,523 graded stocksMethodology v2.0
Financial strength
69.5/100
Price attractiveness
56.9/100
Shareholder Return
76.4/100

As of Sep 2, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SACurrentBCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band A with a total score of 64.5 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 

The 52-week closing range appears once a full year of trading days has accumulated.

Price change by period
1W
19.40%
1M
33.80%
3M
0.60%
1Y
—
Not enough history

As of the Sep 2, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

69.5/100
How much debt does it carry relative to equity?
23.5%
Sector median 51.6%
Sector lowhighTop 22.9% in sector
Can it cover what's due within a year?
485.0%
Sector median 191.7%
Sector lowhighTop 26.9% in sector
How much of revenue becomes profit?
5.5%
Sector median -2.4%
Sector lowhighTop 27.3% in sector
How much did it earn on its own capital?
-1.1%
Sector median -4.5%
Sector lowhighTop 45.1% in sector

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

56.9/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 49.6% in sector
Is the price expensive relative to book value?
1.00x
Sector median 1.61x
Sector lowhighTop 36.6% in sector

Valuation uses the Sep 2, 2026 close and market cap

4

Shareholder Return

Single-indicator axis76.4/100
Does the company actually pay dividends?
0.3%
Sector median 0.0%
Sector lowhighTop 23.6% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩368M
Treasury shares (FY2025)
1,779 shares (0.0% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 2 met · 1 not met · 6 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩789M
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩2.1B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩2.1B vs -₩789M
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not computable

Not computed — required financial data is unavailable

Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026A

Methodology version change (v2.0 applied)

Jul 15, 2026AVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Corporate value-up plan filed

Filed a “기업가치제고계획(자율공시)” (corporate value-up plan, voluntary disclosure) (filed 2026-05-06). View filing ↗

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗
Corporate value-up planMay 6, 2026Source ↗

View in the filings calendar →